| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1084931847 |
| P356 | DOI | 10.1038/SREP46621 |
| P932 | PMC publication ID | 5395940 |
| P698 | PubMed publication ID | 28422178 |
| P50 | author | Adrian V. S. Hill | Q22278197 |
| Sarah Gilbert | Q30513802 | ||
| Katharine A Collins | Q55175774 | ||
| Matthew G. Cottingham | Q55465134 | ||
| P2093 | author name string | Rebecca Snaith | |
| P2860 | cites work | Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants | Q27304735 |
| Protection against malaria at 1 year and immune correlates following PfSPZ vaccination | Q28049695 | ||
| Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites | Q28212476 | ||
| A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants | Q28278852 | ||
| Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites | Q28541281 | ||
| Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein | Q28730561 | ||
| Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-α producing effector and central memory CD4 T cells | Q28742596 | ||
| Characterization of Plasmodium falciparum sporozoite surface protein 2 | Q30044857 | ||
| Genetic engineering of attenuated malaria parasites for vaccination | Q30052742 | ||
| Specific inhibition of the classical complement pathway by C1q-binding peptides. | Q30776720 | ||
| What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines | Q33368617 | ||
| Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data | Q33521372 | ||
| Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses | Q33557760 | ||
| Recombinant protein expression in Pichia pastoris | Q33926665 | ||
| Antibodies against thrombospondin-related anonymous protein do not inhibit Plasmodium sporozoite infectivity in vivo | Q34004839 | ||
| Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial | Q34043843 | ||
| The RTS,S vaccine candidate for malaria | Q34186762 | ||
| Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations | Q34301461 | ||
| Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine | Q34362872 | ||
| Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. | Q34401225 | ||
| Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines. | Q51648048 | ||
| The influence of antigen organization on B cell responsiveness | Q72628042 | ||
| Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation | Q78852123 | ||
| Generation of Transgenic Rodent Malaria Parasites Expressing Human Malaria Parasite Proteins | Q40960433 | ||
| Neutralizing antiviral B cell responses | Q41464284 | ||
| Protection against a malaria challenge by sporozoite inoculation | Q41937865 | ||
| Malaria vaccine technology roadmap | Q43650366 | ||
| Cytotoxic T cells specific for the circumsporozoite protein of plasmodium falciparum | Q44146596 | ||
| High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity | Q45142205 | ||
| Synthesis and assembly of hepatitis B virus surface antigen particles in yeast | Q45793098 | ||
| Reduced immunogenicity of DNA vaccine plasmids in mixtures | Q45872945 | ||
| A topological model for hepatitis B surface antigen | Q47637820 | ||
| Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine | Q47902704 | ||
| Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum | Q47902718 | ||
| Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. | Q47917346 | ||
| Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial | Q47976309 | ||
| Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine | Q48004555 | ||
| Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. | Q48012112 | ||
| A protein particle vaccine containing multiple malaria epitopes | Q48037572 | ||
| Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice | Q34529382 | ||
| A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E | Q34541330 | ||
| Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults | Q34634002 | ||
| The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection | Q34684347 | ||
| From malaria control to eradication: The WHO perspective | Q34984935 | ||
| Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection | Q34990090 | ||
| Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya | Q35165581 | ||
| Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa | Q35428630 | ||
| Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes | Q35553683 | ||
| Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector | Q35741984 | ||
| Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference | Q35771456 | ||
| CD8+ T effector memory cells protect against liver-stage malaria | Q36055733 | ||
| Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization. | Q36285998 | ||
| Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge | Q36313990 | ||
| Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine | Q36353548 | ||
| T cells compete for access to antigen-bearing antigen-presenting cells | Q36376071 | ||
| Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults | Q36393102 | ||
| ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans | Q36460499 | ||
| Tailoring a Combination Preerythrocytic Malaria Vaccine | Q36631331 | ||
| Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers Under Chloroquine Prophylaxis: A Randomized Controlled Trial | Q36644534 | ||
| Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mi | Q36646698 | ||
| Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children | Q37023939 | ||
| Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine | Q37151766 | ||
| Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. | Q37161928 | ||
| Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants | Q37229742 | ||
| Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation | Q37403767 | ||
| Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein | Q37482822 | ||
| Functional immunoassays using an in-vitro malaria liver-stage infection model: where do we go from here? | Q37595803 | ||
| Prime-boost vectored malaria vaccines: progress and prospects | Q37671502 | ||
| The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review | Q38132005 | ||
| Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. | Q38205379 | ||
| Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials | Q38599514 | ||
| Biological role of different antibody classes | Q38757590 | ||
| Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates | Q39823165 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| malaria vaccine | Q6741353 | ||
| P304 | page(s) | 46621 | |
| P577 | publication date | 2017-04-19 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine | |
| P478 | volume | 7 |
| Q92538878 | A Universal Plug-and-Display Vaccine Carrier Based on HBsAg VLP to Maximize Effective Antibody Response |
| Q60914449 | A probabilistic model of pre-erythrocytic malaria vaccine combination in mice |
| Q52678261 | Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model. |
| Q48018507 | An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens. |
| Q66679228 | Bioinspired and Biomimetic Nanotherapies for the Treatment of Infectious Diseases |
| Q90403559 | Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein |
| Q91644203 | Chimeric Murine Polyomavirus Virus-Like Particles Induce Plasmodium Antigen-Specific CD8+ T Cell and Antibody Responses |
| Q60046860 | Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice |
| Q57479092 | Cryo-EM structure of circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts |
| Q59350259 | DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines |
| Q92850206 | Design and assessment of TRAP-CSP fusion antigens as effective malaria vaccines |
| Q100751543 | Discovery of four new B-cell protective epitopes for malaria using Q beta virus-like particle as platform |
| Q92296514 | Diverse Antibody Responses to Conserved Structural Motifs in Plasmodium falciparum Circumsporozoite Protein |
| Q92881172 | Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms |
| Q61803783 | Induction of Plasmodium-Specific Immune Responses Using Liposome-Based Vaccines |
| Q64119844 | Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus |
| Q56362064 | Malaria Vaccines: Recent Advances and New Horizons |
| Q96607419 | Malaria vaccines since 2000: progress, priorities, products |
| Q52623520 | Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. |
| Q55668744 | New Routes and Opportunities for Modular Construction of Particulate Vaccines: Stick, Click, and Glue. |
| Q59800434 | Novel Strategies for Malaria Vaccine Design |
| Q92976912 | Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform |
| Q89514056 | Plasmodium falciparum pre-erythrocytic stage vaccine development |
| Q90214251 | RTS,S/AS01 vaccine (Mosquirix™): an overview |
| Q90725000 | Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials |
| Q57480738 | Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP |
| Q90160111 | Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein |
| Q55336656 | Synergy in anti-malarial pre-erythrocytic and transmission-blocking antibodies is achieved by reducing parasite density. |
| Q92636818 | Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Plasmodium Challenge in a Mouse Model |
| Q56341814 | Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors |
| Q100724843 | Understanding vaccine-elicited protective immunity against pre-erythrocytic stage malaria in endemic regions |
| Q64947790 | Vaccination With Sporozoites: Models and Correlates of Protection. |
Search more.